Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
01 Maggio 2024 - 1:30PM
Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a
biopharmaceutical company committed to enhancing people’s vision
and quality of life through the development and commercialization
of innovative therapies for wet age-related macular degeneration
(wet AMD), diabetic retinopathy, and other diseases and conditions
of the eye, announced plans to report first quarter 2024 financial
results on Tuesday, May 7, 2024, after 4:00 p.m. Eastern Time.
The Company plans to host an Investor Day in New York City on
Thursday, June 13, 2024, in lieu of a first quarter 2024 earnings
conference call. Quarterly earnings conference calls are expected
to resume with the second quarter 2024 financial results.
The Investor Day will include participation from Ocular
Therapeutix senior leadership and key opinion leaders. During the
event, the Company will discuss its corporate strategy and plans
for its retinal disease pipeline. Additional details on the
Investor Day are to follow.
Information about the Company’s quarterly results, conference
calls, webcasts and other investor information are posted on the
Company’s website.
About Ocular
Therapeutix, Inc.Ocular
Therapeutix, Inc. is a biopharmaceutical company committed to
enhancing people’s vision and quality of life through the
development and commercialization of innovative therapies for wet
age-related macular degeneration (wet AMD), diabetic retinopathy
(DR), and other diseases and conditions of the
eye. AXPAXLI™ (axitinib intravitreal implant, also known
as OTX-TKI), Ocular’s product candidate for retinal disease, is
based on its ELUTYX™ proprietary bioresorbable hydrogel-based
formulation technology. AXPAXLI is currently in the first of two
planned pivotal Phase 3 trials for wet AMD,
the SOL-1 trial, and a Phase 1 clinical trial for the
treatment of non-proliferative diabetic retinopathy (NPDR). The
clinical portfolio also includes PAXTRAVA™ (travoprost
intracameral implant, also known as OTX-TIC), currently in a Phase
2 clinical trial for the treatment of primary open-angle glaucoma
or ocular hypertension.
Ocular’s expertise in the formulation, development and
commercialization of innovative therapies of the eye and the ELUTYX
platform supported the development and launch of its first
commercial drug product, DEXTENZA®, an FDA-approved
corticosteroid for the treatment of ocular inflammation and pain
following ophthalmic surgery and ocular itching associated with
allergic conjunctivitis. ELUTYX is also the foundation for two
other clinical-stage assets, OTX-CSI (cyclosporine
intracanalicular insert) for the chronic treatment of dry eye
disease and OTX-DED (dexamethasone intracanalicular
insert) for the short-term treatment of the signs and symptoms of
dry eye disease, as well as several preclinical programs.
Follow us on our website, LinkedIn or X.
DEXTENZA® is a registered trademark of Ocular
Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, and ELUTYX™ and Ocular
Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
About DEXTENZA
DEXTENZA is FDA-approved for the treatment of ocular
inflammation and pain following ophthalmic surgery and ocular
itching associated with allergic conjunctivitis. DEXTENZA is a
corticosteroid intracanalicular insert placed in the punctum, a
natural opening in the inner portion of the lower eyelid, and into
the canaliculus, and is designed to deliver dexamethasone to the
ocular surface for up to 30 days without preservatives. DEXTENZA
resorbs and exits the nasolacrimal system without the need for
removal.
Please see full Prescribing and Safety Information at
the DEXTENZA website.
Forward-Looking StatementsAny statements in
this press release about future expectations, plans, and prospects
for the Company, including the development and regulatory status of
the Company’s product candidates; the potential utility of any of
the Company’s product candidates; the sufficiency of the Company’s
cash resources; the Company’s plans for its upcoming investor day
and future earnings calls; and other statements containing the
words “anticipate”, “believe”, “estimate”, “expect”, “intend”,
“goal”, “may”, “might”, “plan”, “predict”, “project”, “target”,
“potential”, “will”, “would”, “could”, “should”, “continue”, and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors. Such forward-looking statements involve substantial risks
and uncertainties that could cause the Company’s preclinical and
clinical development programs, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the timing and costs involved
in commercializing DEXTENZA or any product or product candidate
that receives regulatory approval; the ability to retain regulatory
approval of DEXTENZA or any product or product candidate that
receives regulatory approval; the initiation, design, timing,
conduct and outcomes of clinical trials, including the SOL-1 trial,
the HELIOS trial, and the planned Phase 3 clinical development
program of AXPAXLI for diabetic retinopathy as well as the
Company’s other ongoing clinical trials; the risk that the FDA will
not agree with the Company’s interpretation of the written
agreement under Special Protocol Assessment for the SOL-1 trial;
the risk that even though the FDA has agreed with the overall
design of the SOL-1 trial, the FDA may not agree that the data
generated by the SOL-1 trial supports potential marketing approval;
uncertainty as to whether the data from earlier clinical trials
will be predictive of the data of later clinical trials,
particularly later clinical trials that have a different design or
utilize a different formulation than the earlier trials, or whether
preliminary or interim data from a clinical trial will be
predictive of final data from such trial; availability of data from
clinical trials and expectations for regulatory submissions and
approvals; the Company’s scientific approach and general
development progress; uncertainties inherent in estimating the
Company’s cash runway, future expenses and other financial results,
including its ability to fund future operations, including clinical
trials; the Company’s existing indebtedness and the ability of the
Company’s creditors to accelerate the maturity of such indebtedness
upon the occurrence of certain events of default; the Company’s
ability to enter into strategic alliances or generate additional
funding on a timely basis, on favorable terms, or at all; and other
factors discussed in the “Risk Factors” section contained in the
Company’s quarterly and annual reports on file with the Securities
and Exchange Commission. In addition, the forward-looking
statements included in this press release represent the Company’s
views as of the date of this press release. The Company anticipates
that subsequent events and developments will cause the Company’s
views to change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so, whether as
a result of new information, future events or otherwise, except as
required by law. These forward-looking statements should not be
relied upon as representing the Company’s views as of any date
subsequent to the date of this press release.
Investors & MediaOcular Therapeutix,
Inc.Bill SlatteryVice President, Investor
Relationsbslattery@ocutx.com
Grafico Azioni Ocular Therapeutix (NASDAQ:OCUL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Ocular Therapeutix (NASDAQ:OCUL)
Storico
Da Lug 2023 a Lug 2024